Browsing Tag
BlueRock Therapeutics
1 post
BlueRock Therapeutics and Bayer dose first patient in clinical trial of iPSC-derived OpCT-001 therapy for vision loss
BlueRock Therapeutics and Bayer AG have dosed the first patient in their Phase 1/2a CLARICO trial of OpCT-001, a novel iPSC-derived therapy targeting primary photoreceptor diseases.